Facebook
Twitter
LinkedIn
Forward
Facilitating Treatment Initiation in Early-Stage Alzheimer Disease
Overview
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
Learning Objectives
- Facilitate prompt treatment initiation for patients who have early-stage AD
Target Audience
Primary care clinicians, psychiatrists, neurologists, and nurse practitioners and physician assistance in these settings
Abstract
Once a diagnosis of Alzheimer disease is established, a wide variety of therapy options are available to treat different stages of the disease. Patients have the opportunity to delay onset of the disease or delay its progression if diagnosed early enough through new FDA-approved disease-modifying treatments. For mild to moderate stages, new symptomatic treatments can slow the progression of the disease and improve symptoms. A multi-component approach is recommended in order to tailor treatments to each patient’s needs.
From the Series: Diagnosing and Treating Alzheimer Disease During the Early Stage
To cite: Burke AD, Goldfarb D. Facilitating Treatment Initiation in Early-Stage Alzheimer Disease. J Clin Psychiatry. 2022;83(4):LI21019DH2C
To share: https://doi.org/10.4088/JCP.LI21019DH2C
© Copyright 2022 Physicians Postgraduate Press, Inc.
Target Audience
Primary care clinicians, psychiatrists, neurologists, and nurse practitioners and physician assistance in these settings
Learning Objectives
Facilitate prompt treatment initiation for patients who have early-stage AD
You may also be interested in
Support Statement
Supported by an educational grant from Lilly USA, LLC.
Learning Objective
After completing this educational activity, you should be able to:
- Facilitate prompt treatment initiation for patients who have early-stage AD
Release, Review, and Expiration Dates
This CME activity was published in May 2022 and is eligible for AMA PRA Category 1 Credit™ through June 1, 2024.
Statement of Need and Purpose
Although early detection and intervention are crucial to slow symptom progression, clinicians are not providing a diagnosis to over half of individuals who meet criteria for dementia. Diagnosis is often not made in the early stage of illness. When clinicians do diagnose Alzheimer's disease (AD), they often do not effectively communicate next steps to patients and care partners, and prompt treatment initiation does not occur in a substantial number of patients newly diagnosed with AD. Clinicians need education on early recognition of AD and on sharing the diagnosis of AD with patients and families. Clinicians also need guidance for providing patients and families with information on next steps and facilitating early treatment initiation for AD. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on Alzheimer disease.
Disclosure of Off-Label Usage
Drs Burke and Goldfarb have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this activity.
Review Process
The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.
Acknowledgment
This activity is derived from the teleconference series “Diagnosing and Treating Alzheimer Disease During the Early Stage,” which was held in February 2022 and supported by an educational grant from Lilly USA, LLC. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.
Faculty Affiliation
Anna D. Burke, MD |
Danielle Goldfarb, MD |
Financial Disclosure
The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:
Dr Burke has served as a consultant for disease state education for Eli Lilly, and Dr. Goldfarb has no personal affiliations or financial relationships with any commercial interest to disclose relative to the activity.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation